Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 15.98
+0.06 (0.38%)
Sep 25, 2026, 1:45 PM CET
Ryvu Therapeutics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 83.94 | 87.7 | 101.96 | 67.3 | 68.44 | 35.41 |
Other Revenue | -0 | - | - | - | - | 0 |
| 83.94 | 87.7 | 101.96 | 67.3 | 68.44 | 35.41 | |
Revenue Growth | -12.51% | -13.98% | 51.51% | -1.67% | 93.25% | -4.16% |
Cost of Revenue | 15.37 | 14.8 | 19.58 | 17.55 | 17.41 | 13.73 |
Gross Profit | 68.57 | 72.9 | 82.38 | 49.74 | 51.03 | 21.69 |
Selling, General & Admin | 124.5 | 152.28 | 183.59 | 123.46 | 84.55 | 64.35 |
Other Operating Expenses | 6.56 | 8.4 | 10.27 | 12.68 | 23.08 | 23.66 |
Operating Expenses | 139.93 | 170.11 | 204.35 | 147.12 | 120.53 | 100.57 |
Operating Income | -71.36 | -97.21 | -121.97 | -97.38 | -69.49 | -78.89 |
Interest Expense | -8.45 | -8.8 | -3.81 | -0.1 | -1.09 | -0.44 |
Interest & Investment Income | 3.4 | 5.09 | 9.13 | 13.83 | 1.15 | 0.06 |
Currency Exchange Gain (Loss) | -0.8 | 0.47 | -1.21 | -4.9 | -0.83 | 0.02 |
Other Non Operating Income (Expenses) | 9.35 | 9.71 | 6.85 | -0 | 0 | 0 |
EBT Excluding Unusual Items | -67.86 | -90.74 | -111.01 | -88.54 | -70.27 | -79.25 |
Gain (Loss) on Sale of Investments | 0.27 | -10.4 | -0.13 | -3.57 | -8.93 | 0.29 |
Pretax Income | -67.59 | -101.14 | -111.14 | -92.11 | -79.2 | -78.96 |
Income Tax Expense | 0.41 | 0.09 | 0.3 | - | 4.59 | 0.12 |
Earnings From Continuing Operations | -68 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Net Income to Company | -68 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Net Income | -68 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Net Income to Common | -68 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 23 | 23 | 23 | 23 | 18 | 18 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 23 | 18 | 18 |
Shares Change | - | - | 0.97% | 24.75% | - | 9.48% |
EPS (Basic) | -2.94 | -4.38 | -4.82 | -4.02 | -4.56 | -4.31 |
EPS (Diluted) | -2.98 | -4.38 | -4.82 | -4.02 | -4.56 | -4.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -85.18 | -121.57 | -135.38 | -93.13 | 15.07 | -70.87 |
Free Cash Flow Per Share | -3.68 | -5.26 | -5.86 | -4.07 | 0.82 | -3.86 |
Gross Margin | 81.69% | 83.12% | 80.80% | 73.91% | 74.57% | 61.24% |
Operating Margin | -85.01% | -110.84% | -119.63% | -144.70% | -101.54% | -222.76% |
Profit Margin | -81.01% | -115.42% | -109.29% | -136.88% | -122.42% | -223.30% |
Free Cash Flow Margin | -101.48% | -138.62% | -132.78% | -138.39% | 22.01% | -200.12% |
EBITDA | -62.71 | -87.99 | -111.76 | -87.32 | -58.16 | -67.94 |
EBITDA Margin | -74.71% | -100.33% | -109.61% | -129.76% | -84.99% | -191.85% |
D&A For EBITDA | 8.65 | 9.22 | 10.22 | 10.05 | 11.33 | 10.95 |
EBIT | -71.36 | -97.21 | -121.97 | -97.38 | -69.49 | -78.89 |
EBIT Margin | -85.01% | -110.84% | -119.63% | -144.70% | -101.54% | -222.76% |
Revenue as Reported | 83.94 | 87.7 | 101.96 | 67.3 | 68.44 | 35.41 |